Pacira spent $50 million buying back 2.2 million shares at an average of $22.28 apiece in Q1 2026 — a striking capital allocation choice for a company whose GAAP net income for the same quarter was just $2.9 million. That math tells you almost everything about how management reads the stock’s discount to intrinsic value, and it frames every other number in the quarter accordingly.
The commercial picture is genuinely improving beneath the headline 5% revenue growth to $177.4 million. EXPAREL’s 7% volume gain is the real signal — volume growth is harder to manufacture than price, and it suggests hospital and surgical center adoption is broadening rather than stalling. ZILRETTA accelerated faster, up 15% to $26.8 million, while iovera° posted 21% growth off a smaller $6.2 million base. The drag came from vial mix shift, GPO discounting tied to last year’s third partnership launch, and storm-related returns in January — all of which are timing noise rather than structural erosion. SG&A climbing to $93.9 million from $86.8 million year-over-year is less forgivable and deserves scrutiny; selling expense growing faster than revenue is a compression problem, not a growth story.
The strategic bet Pacira is running is label expansion as a moat-deepening exercise. ZILRETTA already owns the knee OA intra-articular corticosteroid space; a positive shoulder OA readout later this year would make it the first product with an on-label indication for that joint, immediately ahead of any competitor attempting the same path. That label would not just add a prescribing category — it would give Pacira a reimbursement and formulary argument that generics and off-label alternatives cannot match. The PCRX-201 Phase 2 Part A data in knee OA adds another dimension: if that gene therapy signal holds, Pacira stops being a regional anesthesia company and becomes something considerably harder to displace.
The number to track is ZILRETTA net product sales in Q3, the first full quarter after the shoulder OA topline readout drops. Physician pull-through on a new label indication happens fast in orthopedics or it doesn’t happen at all — that single quarter will answer whether the expansion thesis justifies the buyback aggression at current valuations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
